Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma Approval offers access to new treatment options for newly diagnosed ...

AN2 Therapeutics, Inc. , a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced its submission ...

Allogene Therapeutics is undervalued. Read more on ALLO stock's cash runway, innovative CAR-T therapies, and market expansion ...

Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma Approval offers access to new treatment options for newly diagnosed MM patients Approval based on positive results from ...

Today marks a significant milestone in Ghana's history - the 59th anniversary of the overthrow of our country's first ...

Odronextamab demonstrated a manageable safety profile and generated durable responses in patients with R/R DLBCL who have ...

We recently published a list of 10 Oversold Biotech Stocks to Buy Now. In this article, we are going to take a look at where ...

Vor Biopharma's trem-cel offers hope for AML treatment, but financial risks and early-stage progress suggest caution. Learn ...

DelveInsight's HPV16-Positive Head and Neck Squamous Cell Carcinoma Market Insights report includes a comprehensive understanding of current treatment practices, HPV16+ HNSCC emerging drugs, market ...

Rhumbline Advisers lowered its holdings in shares of Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 2.7% during the fourth ...

CIBC Asset Management Inc raised its holdings in Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 14.0% in the fourth ...